ERGOCALCIFEROLUM
Muscle Weakness
Brigham and Women's HospitalSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Muscle Weakness cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
bio101 Biophytis | Phase 2 | B |
Solu-Cortef Mahidol University | Phase 2 | CCC |
Same molecule, other indications
ERGOCALCIFEROLUM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →